Roche chooses to develop Genmab antibodies

May 2004
PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p8
Market Research Report
Focuses on the selection of two Genmab AS antibodies by Roche as candidates for clinical development. Terms of the agreement; Production of antibody product candidates; Effectivity of the development of antibodies.


Related Articles

  • ROCHE SELECTS TWO GENMAB ANTIBODIES AS CLINICAL CANDIDATES.  // Worldwide Biotech;May2004, Vol. 16 Issue 5, p1 

    Reports on the decision of Roche to select Genmab antibodies as candidates for clinical development. Terms of agreement between Roche and Ganmab AS; Value of Genmab and Roche collaboration; Background of Genmab.

  • ROCHE/GLYCART TO DISCOVER NEW THERAPEUTIC ANTIBODIES.  // Worldwide Biotech;Nov2004, Vol. 16 Issue 11, p5 

    Reports on the agreement between Roche and GLYCART to discover next-generation therapeutic antibodies using GlycoMabTM technology. Terms of the agreement; Factors that influenced Roche to license GlycoMabTM; Profile of GLYCART and Roche; Information on GlycoMab.

  • Biotechnology.  // PharmaWatch: Monthly Review;May 2004, Vol. 3 Issue 5, p44 

    Reports global developments on biotechnology as of March 15, 2004. Purchasing deal between Amgen Inc. and Tularik Inc.; Partnership between Genmab AS and Roche Pharmaceuticals company; Research and discovery collaboration agreement between NeoGenesis Pharmaceuticals Inc. and AstraZeneca PLC.

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p2 

    Reports global developments related to biotechnology as of May 2004. Acquisition of Tularik Inc. by Amgen Inc.; Consolidation of Genmab AS and Roche; Collaboration agreement between NeoGenesis Pharmaceuticals Inc. and AstraZeneca PLC.

  • Goodbye Genentech, But No Obit for Biotech Yet, Please. Boggs, Jennifer // BioWorld Today;3/16/2009, Vol. 20 Issue 49, p1 

    The article focuses on the possible impact of the merger between Roche Holdings AG and Genentech Inc. on the biotechnology industry. In the said deal, Roche agreed to acquire the remaining shares of Genentech priced at $95 per share. Some speculate that the merger could have a large impact on...

  • Breast Cancer Update.  // PharmaWatch: Cancer;Dec2006, Vol. 5 Issue 12, p9 

    No abstract available.

  • Patheon arm inks drug deal with Roche.  // European Chemical News;6/16/2003, Vol. 78 Issue 2057, p28 

    Reports on an agreement between the Italian subsidiary of drug development and manufacturing services company Patheon with Roche designed to supply solid, liquid and sterile products for the European market. Duration of the agreement; Estimated revenues from the contract; Background information...

  • Transgene In Line For €10M Milestone On CIN Compound. Etheridge, James // BioWorld International;6/6/2007, Vol. 12 Issue 23, p3 

    The article reports on the agreement signed by Transgene SA with F. Hoffman-La Roche Ltd., after obtaining approval from the U.S. Federal Drug Administration and the European Medicines Agency (EMEA) for its planned Phase III trial of TG 4001/R3484 (MVA-HPV-IL2), which is being developed for the...

  • Synta Lands Preclinical CRACM Deal with Roche, $25M Up Front. Boggs, Jennifer // BioWorld Today;1/5/2009, Vol. 20 Issue 1, p1 

    This article reports on the agreement signed by Synta Pharmaceuticals Corp. with F. Hoffman-La Roche Ltd. for up to three compounds targeting calcium release-activated calcium (CRAC) modulator channels for treating inflammatory diseases. An up-front payment worth $25 million is included in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics